

Evaluation of AXS-05 (dextromethorphan-bupropion) in Major Depressive Disorder Using the Interest-Activity Domain

Roger S. McIntyre,^{1,2} Sagar V. Parikh,³ Rakesh Jain,⁴ Zachariah Thomas,⁵ Graham Eglit,⁵ Candace Andersson,⁵ Herriot Tabuteau⁵

¹University of Toronto, Toronto, ON, Canada; ²Brain and Cognition Discovery Foundation, Toronto, ON, Canada; ³University of Michigan, Ann Arbor, MI, USA; ⁴Texas Tech University - Permian Basin, Midland, TX, USA; ⁵Axsome Therapeutics, New York, NY, USA

Key Questions

- Does AXS-05 improve interest-activity symptoms in people with MDD?
- Does severity of interest-activity symptoms at baseline impact depression outcomes with AXS-05 treatment?

Conclusions

- In people with MDD, prominent interest-activity symptoms (low interest, reduced activity, indecisiveness, and lack of enjoyment) at baseline are associated with poor treatment response to serotonergic antidepressants
- This post hoc analysis evaluated the interest-activity symptom score, a newer measure derived from the MADRS and QIDS-SR
- AXS-05, an oral NMDA receptor antagonist and sigma-1 receptor agonist, significantly improved interest-activity symptom scores compared with control
- AXS-05 exhibited comparable reductions in depressive symptoms regardless of severity of baseline interest-activity symptoms
- These results suggest that AXS-05 may be a particularly effective treatment option in individuals with MDD who have substantially impaired interest and activity

References

- Kadriu B, et al. *Int J Neuropsychopharmacol*. 2019;22(2):119-135.
- Rush AJ, et al. *J Clin Psychiatry*. 2020;81(5):19m12949.
- Uher R, et al. *Psychol Med*. 2012;42(5):967-980.
- Uher R, et al. *J Clin Psychiatry*. 2020;81(4):9256.
- Auvelity [package insert]. New York, NY, USA: Axsome Therapeutics, Inc.; 2022.
- Iosifescu DV, et al. *J Clin Psychiatry*. 2022;83(4):41226.
- Tabuteau H, et al. *Am J Psychiatry*. 2022;179(7):490-499.

Acknowledgments

This study was funded by Axsome Therapeutics. Sarah Engelberth, PhD, and Kendall Foote, PhD, of Nucleus Global, an INIZIO company, provided medical writing and editorial support for this poster, which was funded by Axsome Therapeutics.


Disclosures

R. McIntyre has received research grant support from CHIR/GACD/National Natural Science Foundation of China (NSFC); speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neurocr Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kiri, Sanofi, Eisai, Intra-Cellular Therapies, Inc., Newbridge Pharmaceuticals, AbbVie, and Atal Life Sciences. He is a CEO of Broxia Scientific Corp.

S. Parikh has served as a consultant for Alkermes, Axsome, Boehringer Ingelheim, Janssen, Menarino, Neomind, Sage Therapeutics, and Takeda; he has received speaking honoraria from CANMA and Otsuka and CME honoraria from Otsuka; he has received research grants from Axsome, the Canadian Institutes for Health Research, the Ethel and James Finn Foundation, Janssen, Merck, the Ontario Brain Institute, Sage Therapeutics, and Takeda; and he holds shares in Menarino and Neomind.

R. Jain has served as a consultant to Alkermes, Allergan (now AbbVie), Avanti, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva; paid speaker for Alkermes, Allergan (now AbbVie), Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, and Tris Pharmaceuticals; received research support from Allergan (now AbbVie), AstraZeneca, Lilly, Lundbeck, Otsuka, Pfizer, Shire, and Takeda; and served on advisory boards for Alkermes, Alkermes, Avanti, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva.

Z. Thomas, G. Eglit, C. Andersson, and H. Tabuteau are employees of Axsome Therapeutics.



American College of Neuropsychopharmacology (ACNP), December 3-6, 2023, Tampa FL


Introduction

- Major depressive disorder (MDD) is a highly prevalent, chronic, disabling disorder and a leading cause of suicide¹
- In people who respond to monoaminergic antidepressants, it often takes weeks to observe clinically meaningful improvements in depression symptoms²
- Serotonergic antidepressants have demonstrated reduced effectiveness in people with depression who have prominent symptoms of impaired interest and activity (low interest, reduced activity, indecisiveness, and lack of enjoyment), a finding that has been replicated in multiple studies, including:
 - Genome-based Therapeutic Drugs for Depression (GENDEP; N=811)³
 - Sequenced Treatment Alternatives to Relieve Depression (STAR*D; a subgroup of N=3637)³
 - Canadian Biomarker Integration Network in Depression trial 1 (CAN-BIND-1; N=211)⁴
- Therefore, alternative, mechanistically novel antidepressants are needed for individuals with MDD who have impairments in interest and activity

AXS-05: A Novel, Oral NMDA Receptor Antagonist

- AXS-05 (dextromethorphan-bupropion [Auvelity® extended-release tablet]) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved by the US Food and Drug Administration for the treatment of MDD in adults (Figure 1)⁵
 - Dextromethorphan is an antagonist of the NMDA receptor and a sigma-1 receptor agonist⁵
 - Bupropion is an aminoketone and cytochrome P450 2D6 inhibitor that increases the bioavailability of dextromethorphan⁵

Figure 1. AXS-05 mechanism of action



Key Findings

Patient Population

- Baseline demographics and clinical characteristics were similar between groups (Table 2)


	AXS-05 (n=199)	Control (n=199)
Age, mean (SD), years	41.0 (12.8)	40.5 (13.5)
Women, n (%)	120 (60)	143 (72)
Race, n (%) ^a		
White	114 (57)	112 (56)
Black	70 (35)	68 (34)
Asian	10 (5)	8 (4)
Other ^b	5 (3)	11 (6)
Prior antidepressant treatment during the current MDE, n (%) ^c		
No prior treatment	155 (78)	135 (68)
Prior treatment	44 (22)	64 (32)
Depression severity, n (%)		
MADRS total score <35	131 (66)	130 (65)
MADRS total score ≥35	68 (34)	69 (35)
MADRS total score, mean (SD)	33.2 (4.40)	32.9 (4.40)
Interest-activity symptom score, mean (SD)	22.6 (4.51)	22.4 (4.77)

^a May not sum to 100% due to rounding. ^b Includes American Indian or Alaska Native, Native Hawaiian or Pacific Islander, multiple races, other, or not reported. ^c Individuals with treatment-resistant depression (defined as having had ≥2 failed adequate antidepressant treatments in the current MDE) were excluded from ACNP and GENDEP. MADRS, Montgomery Åsberg Depression Rating Scale; MDE, major depressive episode.

Hypothesis 1. AXS-05 would produce greater improvement in interest-activity compared with control

- AXS-05 treatment significantly improved change from baseline (reduced score) in interest-activity symptom score compared with placebo at every time point (Figure 3A)
- A significantly greater percentage of people achieved interest-activity symptom score response with AXS-05 compared with placebo at every time point (Figure 3B)


Figure 3. Interest-activity symptom score^a change from baseline (A) and response (B)



Methods & Study Design

- This post hoc analysis pooled data from 2 double-blind, randomized, controlled, 6-week trials of AXS-05 in individuals with moderate to severe MDD
 - The GEMINI trial (NCT04019704) was placebo controlled (AXS-05, n=156; placebo, n=162)⁶
 - The ASCEND trial (NCT03595579) used bupropion as an active control (AXS-05, n=43; bupropion, n=37)⁷
- Both studies met their primary endpoint, with AXS-05 demonstrating statistically significant improvement on the Montgomery Åsberg Depression Rating Scale (MADRS) compared with control^{6,7}
- This analysis investigated the interest-activity symptom score, which has been used previously⁴ and is defined by the sum of 3 MADRS items (concentration, lassitude, and inability to feel) and 3 Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) items (concentration, interest, and energy) (Figure 2)⁴

Figure 2. Interest-activity symptom score components



^a As reported previously⁴ the QIDS-SR items (with scores from 0 to 3) were doubled for equal weight with the MADRS items (with scores from 0 to 6). MADRS, Montgomery Åsberg Depression Rating Scale; QIDS-SR, Quick Inventory of Depressive Symptomatology, Self-Report.

- This post hoc pooled analysis evaluated 2 hypotheses (Table 1)


Hypothesis	Statistical method
1. AXS-05 would produce greater improvement in interest-activity change from baseline compared with control	MMRM using unstructured variance-covariance structure was fit with change from baseline in interest-activity. Fixed effects consisted of baseline interest-activity score, treatment group, week, and the interaction of treatment group and week. Treatment effects (differences from placebo) were estimated based on estimated marginal means at each treatment week and overall by marginalizing across treatment weeks. Responder analyses conducted evaluating probabilities of achieving ≥50% reduction from baseline in interest-activity scores with Chi square test
2. Efficacy of AXS-05 would be maintained regardless of individuals' baseline severity of interest-activity score	MMRM assuming an unstructured variance-covariance structure was fit with MADRS change from baseline as the outcome. Fixed effects consisted of baseline MADRS score, treatment group, week, baseline interest-activity score, treatment group x week, treatment group x baseline interest-activity score, week x baseline interest-activity score, and the 3-way interaction between treatment group, week, and baseline interest-activity score. Simple slopes were evaluated

MADRS, Montgomery Åsberg Depression Rating Scale; MMRM, mixed model for repeated measures.

Hypothesis 2. Efficacy of AXS-05 would be maintained regardless of individuals' baseline severity of interest-activity score

- In the control group, higher baseline interest-activity impairment was associated with less improvement in MADRS total score (simple slopes b, 0.27; 95% CI, 0.02 to 0.52; P<.05) (Online Figure)
- There was no significant association between baseline interest-activity symptom score with MADRS total score in the AXS-05 group (simple slopes b, -0.04; 95% CI, -0.24 to 0.31; P=.787)
 - There was no association between baseline interest-activity symptom score and MADRS change from baseline in the AXS-05 group at any treatment week (all P values >.05)
- Changes from baseline in MADRS total score were similar among participants with low, average, and high baseline interest-activity symptom scores throughout the trial in the AXS-05 treatment group, but differed in the control treatment group (Figure 4)
 - In the control group, high baseline interest-activity symptom scores were associated with less improvement in depression symptoms

Figure 4. Change in MADRS total score by baseline interest-activity symptom score^a



^a The interest-activity symptom score is the sum of 3 MADRS items (concentration, lassitude, and inability to feel) and 3 QIDS-SR items (concentration, interest, and energy). Higher interest-activity symptom score corresponds to more severe symptoms. High interest-activity is 1 SD above the mean in baseline interest-activity symptom score, average interest-activity score reflects mean baseline interest-activity symptom score, and low interest-activity score reflects 1 SD below the mean in interest-activity symptom score. ^b Marginal means for MADRS change from baseline scores. MADRS, Montgomery Åsberg Depression Rating Scale; QIDS-SR, Quick Inventory of Depressive Symptomatology, Self-Report.

Safety

- The most commonly reported adverse reactions (≥5% and twice the rate of placebo) with AXS-05 were dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis